MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from atm
$2,077K
Proceeds from private
placement
$1,375K
Net cash provided by
financing activities
$3,322K
Canceled cashflow
$130K
Net increase
(decrease) in cash and cash...
$8K
(100.18%↑ Y/Y)
Canceled cashflow
$3,314K
Issuance costs paid for
private placement
-$130K
Share-based compensation
expense
$441K
(-29.44%↓ Y/Y)
Accrued research and
development costs
$146K
(484.21%↑ Y/Y)
Accounts payable
$118K
(126.52%↑ Y/Y)
Prepaid expenses
-$37K
(-76.19%↓ Y/Y)
Other current assets
-$5K
(-200.00%↓ Y/Y)
Net cash used in
operating activities
-$3,314K
(23.52%↑ Y/Y)
Canceled cashflow
$747K
Net loss
-$3,528K
(-15.41%↓ Y/Y)
Accounts receivable
$444K
(-20.14%↓ Y/Y)
Accrued expenses and
other current...
-$89K
(82.72%↑ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)